Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas.

Elisa Genuardi, Beatrice Alessandria, Aurora Maria Civita, Simone Ferrero

Open access · hybridAbstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 75% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Elisa GenuardiHematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.

Beatrice AlessandriaHematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.

Aurora Maria CivitaHematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.

Simone FerreroHematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy. simone.ferrero@unito.it.

University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although MRD monitoring by the classic polymerase chain reaction (PCR) approach is a powerful outcome predictor, about 20% of mantle cell lymphoma (MCL) and 50% of follicular lymphoma (FL) patients still lack a molecular marker and are thus resulting not eligible for MRD monitoring. Targeted locus amplification (TLA), a new NGS technology, has been revealed as a feasible marker screening approach able to identify uncommon B-cell leukemia/lymphoma 1 (BCL1) and B-cell leukemia/lymphoma 2 (BCL2) rearrangements in MCL and FL cases defined as having "no marker" by the classic PCR approach.

Indexed as

Lymphoma, B-CellLymphoma, Mantle-CellAdultBiomarkersGene RearrangementHumansImmunoglobulin Heavy ChainsTranslocation, GeneticBiomarkersImmunoglobulin Heavy ChainsFollicular lymphomaImmunoglobulinMantle cell lymphomaMolecular markerNext-generation sequencingTargeted locus amplificationTranslocations

Identifiers

PMID35622324

DOI10.1007/978-1-0716-2115-8_8

PMCPMC9761915

OpenAlexW4285184660

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.